LPCN vs. TCRT, ACST, ZIVO, LIAN, ORGS, BCLI, TNXP, PHXM, BNOX, and SABS
Should you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include Alaunos Therapeutics (TCRT), Acasti Pharma (ACST), ZIVO Bioscience (ZIVO), LianBio (LIAN), Orgenesis (ORGS), Brainstorm Cell Therapeutics (BCLI), Tonix Pharmaceuticals (TNXP), PHAXIAM Therapeutics (PHXM), Bionomics (BNOX), and SAB Biotherapeutics (SABS). These companies are all part of the "medical" sector.
Lipocine (NASDAQ:LPCN) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, community ranking, risk and profitability.
Lipocine has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -0.33, meaning that its stock price is 133% less volatile than the S&P 500.
Lipocine received 336 more outperform votes than Alaunos Therapeutics when rated by MarketBeat users. Likewise, 70.58% of users gave Lipocine an outperform vote while only 58.33% of users gave Alaunos Therapeutics an outperform vote.
Lipocine's return on equity of -63.28% beat Alaunos Therapeutics' return on equity.
Lipocine has higher revenue and earnings than Alaunos Therapeutics. Lipocine is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Lipocine had 2 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 2 mentions for Lipocine and 0 mentions for Alaunos Therapeutics. Lipocine's average media sentiment score of 0.00 equaled Alaunos Therapeutics'average media sentiment score.
9.1% of Lipocine shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 5.0% of Lipocine shares are owned by insiders. Comparatively, 6.2% of Alaunos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Lipocine beats Alaunos Therapeutics on 8 of the 12 factors compared between the two stocks.
Get Lipocine News Delivered to You Automatically
Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipocine Competitors List
Related Companies and Tools
